X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DSP107, a dual, first-in-class CD47 and 4-1BB targeting fusion protein that activates innate and adaptive immunity, is being developed in combination with atezolizumab, an anti-PD-L1 in patients with advanced solid tumors.
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
DSP107 is a dual-targeting fusion protein that activates innate and adaptive immunity by blocking CD47 on cancer cells and utilizing 4-1BB conditional co-stimulatory activation of T-cells.
Lead Product(s): DSP107
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Myeloma Investment Fund
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 17, 2022
Details:
Proceeds will enable further clinical development of DSP107, a first-in-class CD47x41BB targeting fusion protein, for the treatment of solid and hematological tumors and accelerate the path towards clinical development of the Company's preclinical pipeline.
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: aMoon
Deal Size: $46.5 million Upfront Cash: Undisclosed
Deal Type: Financing June 16, 2021
Details:
Under the terms of the agreement, Samsung Biologics will provide its end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR’s drug candidate DSP502, a TIGITxPD1 fusion protein.
Lead Product(s): DSP502
Therapeutic Area: Oncology Product Name: DSP502
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Samsung Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 02, 2021
Details:
DSP107 uniquely delivers a multilayered attack by binding cancer cells and T-cells to produce a targeted synergistic effect, combining immune checkpoint inhibition with selective T-cell activation.
Lead Product(s): DSP107,Azacitidine
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Focus Fund
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 26, 2021
Details:
Under the agreement, Thomas Jefferson University is granting KAHR an exclusive license to develop and commercialize multiple new drug candidates including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein for immuno-oncology.
Lead Product(s): TIGITxPD1 fusion protein
Therapeutic Area: Oncology Product Name: DSP502
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kahr Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 01, 2021
Details:
Study to be conducted in two parts. The first part will evaluate the safety, pharmacokinetics and pharmacodynamics of DSP107 as a monotherapy and in combination with Roche's PD-L1-blocking checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors.
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Under this IND, the Company intends to initiate a Phase I/II clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of DSP107 as a monotherapy and in combination with Roche's atezolizumab (Tecentriq®) in patients with advanced solid tumors.
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
Proceeds will be used for advancing the Company's next generation immuno-oncology drug candidates including the clinical development of the Company's lead product, DSP107, an anti-CD47 therapy.
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flerie Invest AB
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
